TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24336090
Drug: Teacher-led daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teacher-led daily 10-minute stress management intervention for 4 months
Study: 24336090
Drug: Control class
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control class (reading from a children's book for 10 minutes daily)
Study: 2093126
Drug: Propranolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (10 mg) with Quinidine (100 mg)
Study: 2093126
Drug: Propranolol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (20 mg) with Quinidine (200 mg)
Study: 21680059
Drug: High-flow oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow oxygen (100% oxygen at 15 L/minute by nonrebreather mask for 5 minutes before and during sedation)
Study: 21680059
Drug: Compressed air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compressed air (15 L/minute by nonrebreather mask for 5 minutes before and during sedation)
Study: 24622243
Drug: sST2 <33.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: sST2 <33.2 ng/mL
Study: 24032185
Drug: Conventional acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional acupuncture and massage therapy
Study: 18835318
Drug: 2-dose recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose recombinant vaccine
Study: 18835318
Drug: 3-dose recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-dose recombinant vaccine
Study: 18835318
Drug: 3-dose plasma-derived
Normalized name: c1-inhibitor, plasma derived
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-dose plasma-derived vaccine
Study: 15297847
Drug: Thalidomide plus
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide plus oral melphalan (TM group)
Study: 8345035
Drug: CGS 20267
Normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGS 20267 (0.1 mg)
Study: 8345035
Drug: CGS 20267
Normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGS 20267 (0.5 mg)
Study: 8345035
Drug: CGS 20267
Normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGS 20267 (2.5 mg)
Study: 31027435
Drug: AMPH EROS
Normalized name: AMPH-b
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AMPH EROS 18.8 mg under fed conditions
Study: 31027435
Drug: AMPH EROS
Normalized name: AMPH-b
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AMPH EROS 18.8 mg under fasted conditions
Study: 31027435
Drug: IR MAS
Normalized name: SALICYLIC ACID 20 mg in 1 mL TOPICAL CREAM [Dandruff Repair Mask]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IR MAS 30 mg under fasted conditions
Study: 25250647
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 600 mg intravenous, administered 1 hr before and 2 hr after cerebral angiography.
Study: 19165664
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (triptorelin 0.2 mg, n = 106)
Study: 14762743
Drug: Closed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed treatment without surgical reduction (n = 44)
Study: 2884706
Drug: Broxaterol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broxaterol 0.5 mg
Study: 2884706
Drug: Salbutamol 4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol 4.0 mg
Study: 26793956
Drug: Continued thienopyridine
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued thienopyridine plus aspirin
Study: 16450594
Drug: Prophylactic intravenous
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic intravenous lidocaine 1 mg/kg
Study: 16450594
Drug: Therapeutic intravenous
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic intravenous lidocaine 0.5 mg/kg
Study: 10569330
Drug: HPMC 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPMC 2.5 g/day
Study: 10569330
Drug: HPMC 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPMC 5.0 g/day
Study: 10569330
Drug: HPMC 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPMC 7.5 g/day
Study: 6313522
Drug: twice-daily placebo
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: twice-daily placebo (n = 77)
Study: 6313522
Drug: twice-daily captopril
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: twice-daily captopril 25 mg (n = 77)
Study: 6313522
Drug: twice-daily captopril
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: twice-daily captopril 50 mg (n = 71)
Study: 6313522
Drug: twice-daily captopril
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: twice-daily captopril 100 mg (n = 69)
Study: 30924570
Drug: Low carbohydrate
Normalized name: Low carbohydrate beer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low carbohydrate diet (LCD < 100 g carbohydrate/d)
Study: 30924570
Drug: High carbohydrate
Normalized name: High carbohydrate food
Approvals — FDA: no, EMA: no, PMDA: no
Description: High carbohydrate diet (HCD > 250 g carbohydrate/d)
Study: 30217492
Drug: Nonprotocol therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonprotocol therapy
Study: 27535063
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptives (COCs) containing 30μg ethinylestradiol (EE) and 3mg drospirenone (DRSP) in a 21/7 regimen
Study: 22963592
Drug: Nonblind clinician
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonblind clinician and patient ratings of treatment response
Study: 21526664
Drug: Fentanyl pretreatment
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl pretreatment (1 microg/kg diluted in saline to a volume of 5 ml)
Study: 21526664
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 ml normal saline)
Study: 17693179
Drug: Sapropterin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sapropterin (10 mg/kg, oral, once daily for 6 weeks)
Study: 17693179
Drug: Placebo (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral, once daily for 6 weeks)
Study: 10323379
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose GH treatment (66 or 100 microg/kg x day s.c. over 2 years)
Study: 10323379
Drug: Second course
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second course of GH treatment (66 microg/kg x day s.c.)
Study: 10323379
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further GH treatment after initial GH withdrawal (mean adjusted height SD score -2.7, n = 13)
Study: 10323379
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further GH treatment after initial GH withdrawal (mean adjusted height -3.3 SD score, n = 9)
Study: 6120705
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of midazolam (Ro 21‐3981, Dormicum) administered p.o.
Study: 6120705
Drug: 7 mg
Normalized name: pectin 7 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 mg of oxazepam administered p.o.
Study: 19915080
Drug: 4 individualized
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 individualized counselor-led MI sessions and nicotine replacement therapy (NRT)
Study: 15506574
Drug: Pen-tablet computers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pen-tablet computers for data collection
Study: 16325299
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion algorithm
Study: 1804386
Drug: 5-fluorouracil-leucovorin combination
Normalized name: fluorouracil, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil-leucovorin combination with allopurinol
Study: 1804386
Drug: 5-fluorouracil-leucovorin combination
Normalized name: fluorouracil, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil-leucovorin combination without allopurinol
Study: 6376916
Drug: 30-g protein-restricted
Normalized name: pegvisomant
DrugBank: Pegvisomant (DB00082)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 30-g protein-restricted diet supplemented by keto acids
Study: 31214846
Drug: Three-step yoga
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-step yoga program for T2DM, details on dosage and duration not specified.
Study: 25116969
Drug: Visible light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visible light (sham treatment)
Study: 15035598
Drug: Control (Inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Inhaled corticosteroid therapy)
Study: 12453333
Drug: 5-fluorouracil-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil-based chemotherapy with radiation
Study: 11475715
Drug: Buyang Huanwu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buyang Huanwu Decoction (BHD) combined with western medicine (prednisone acetate and cytoxan)
Study: 11475715
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (prednisone acetate and cytoxan) with aspirin and persantin
Study: 7544731
Drug: Finasteride treatment
Normalized name: Finasteride
DrugBank: Finasteride (DB01216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Finasteride treatment for 5 years
Study: 31112079
Drug: Misoprostol 200
Normalized name: MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 200 µg applied vaginally 10 hours and 4 hours prior to IUD insertion
Study: 31112079
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet applied vaginally 10 hours and 4 hours prior to IUD insertion
Study: 28319872
Drug: Intrathecal baclofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal baclofen (ITB) bolus injection, 50-μg
Study: 25878371
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose (500 mg) of IV methylprednisolone
Study: 25878371
Drug: 10 days
Normalized name: AlleRx 10-day Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 days of oral prednisolone
Study: 17005502
Drug: OPTIMISE programme
Normalized name: PUMP,LUTREPULSE PROGRAMMABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPTIMISE programme (treatment group)
Study: 9863109
Drug: RBUD-1 (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBUD-1 (a preparation of Chinese herbal medicine)
Study: 9863109
Drug: Composite prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Composite prescription of Western and Chinese medicine
Study: 30457358
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric carboxymaltose treatment
Study: 24597472
Drug: Idrabiotaparinux (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idrabiotaparinux (3 mg weekly for the first 7 weeks, then 2 mg, adjusted to 1.5 mg for certain patients)
Study: 24597472
Drug: Warfarin (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (daily with dose adjustment to maintain INR between 2.0 and 3.0)
Study: 21169087
Drug: PET scan
Normalized name: Pet Pectillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET scan before treatment
Study: 21169087
Drug: PET scan
Normalized name: Pet Pectillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET scan after 6 months of treatment
Study: 19932833
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac sodium 1% gel (DSG) 4 g, applied 4 times daily for 12 weeks
Study: 19932833
Drug: Vehicle (placebo)
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (placebo) 4 g, applied 4 times daily for 12 weeks
Study: 12609785
Drug: LHA formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHA formulation (2-hydroxy-5-octanoyl benzoic acid), applied twice daily for 2 weeks
Study: 10338051
Drug: Alkalinized local
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alkalinized local anaesthesia (LA) solution (n = 19)
Study: 10338051
Drug: Non-alkalinized local
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-alkalinized local anaesthesia (LA) solution (n = 21)
Study: 10338051
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream with local anaesthesia and patient-controlled analgesia with alfentanil
Study: 8520498
Drug: Intron A
Normalized name: Intron A
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intron A (3 mega units/m2 s.c. three times weekly)
Study: 3551617
Drug: Ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac tromethamine 0.5% ophthalmic solution
Study: 7203334
Drug: Neostigmine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (0.5 mg per single dose)
Study: 7203334
Drug: Dihydroergotamine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergotamine (1 mg)
Study: 24597650
Drug: RehabMaster intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RehabMaster intervention plus conventional occupational therapy (10 sessions)
Study: 24597650
Drug: Conventional occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional occupational therapy only (OT-only group)
Study: 15914127
Drug: St. John's
Normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St. John's Wort 300 mg three times daily
Study: 15914127
Drug: Low-dose OC
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose OC (Loestrin 1/20) with placebo
Study: 12626213
Drug: Low-dose estrogen-progestin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose estrogen-progestin therapy (1 mg 17beta-estradiol with 500 micro g norethisterone acetate daily)
Study: 10337434
Drug: Patanol (olopatadine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patanol (olopatadine hydrochloride 0.1% ophthalmic solution)
Study: 10337434
Drug: Claritin (loratadine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Claritin (loratadine, 10 mg tablet)
Study: 8527539
Drug: Ciprofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (500 mg daily for 3 days)
Study: 2736055
Drug: Biosynthetic human
Normalized name: Proinsulin biosynthetic human
DrugBank: Proinsulin human (DB17875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biosynthetic human growth hormone (somatropin)
Study: 24425697
Drug: Emergency medical
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emergency medical services treatment for ACS
Study: 20417572
Drug: Maintenance group
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance group (optimal therapeutic doses continued throughout the study)
Study: 20417572
Drug: 26-week group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 26-week group (optimal therapeutic doses continued for 26 weeks, followed by a 50% dose reduction maintained until the end of the study)
Study: 20417572
Drug: 4-week group
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week group (optimal therapeutic doses continued for 4 weeks, followed by a 50% dose reduction maintained until the end of the study)
Study: 20417572
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three treatment groups
Study: 18355330
Drug: Raisin consumption
Normalized name: triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Raisin consumption (90 g/day)
Study: 16627548
Drug: Supportive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive therapy plus placebo medication
Study: 9103748
Drug: Anger treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anger treatment (12-session cognitive-behavioral treatment)
Study: 3902480
Drug: GM1 ganglioside
Normalized name: Porcine GM1 ganglioside
DrugBank: Ganglioside GM1 (DB16948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM1 ganglioside (40 mg/day i.m. injection) for 6 weeks
Study: 30172407
Drug: Cr supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cr supplementation (0.05 mg of Cr/kg of body weight0.75)
Study: 30172407
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no Cr supplement; Cr‐)
Study: 27310977
Drug: Nitazoxanide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitazoxanide (500 mg bid), levofloxacin (500 mg once daily), omeprazole (40 mg bid), doxycycline (100 mg twice daily) for 14 days
Study: 24902655
Drug: Individualized goal-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized goal-directed therapy (IGDT) with transthoracic echocardiography (TTE) and pulse-contour device (FloTrac™)
Study: 24902655
Drug: Individualized goal-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized goal-directed therapy (IGDT)
Study: 20816468
Drug: Antimigrainous medication
Normalized name: ANTIMIGRAINE AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimigrainous medication for treating single attacks and preventing recurring attacks
Study: 10429625
Drug: Ifosfamide and
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ifosfamide and continuous infusion of etoposide with growth factor
Study: 10429625
Drug: Adjuvant ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant ifosfamide and doxorubicin treatment after primary surgery
Study: 10429625
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy for localized resectable STS
Study: 8666123
Drug: Menorest® (adhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menorest® (adhesive matrix transdermal system) used in combination with dydrogesterone for 12 days in each cycle
Study: 8666123
Drug: Menorest® (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menorest® (twice weekly application)
Study: 1869005
Drug: Iron medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron medication (2 x 1 Aktiferrin comp. Kps. during pregnancy starting from the 22nd week)
Study: 1869005
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication during pregnancy (control group)
Study: 6718333
Drug: Oxytocin (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin (administered intravenously and/or intranasally)
Study: 27411267
Drug: Compression dressing
Normalized name: oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Compression dressing therapy (observation group, n = 17)
Study: 27411267
Drug: Ordinary dressing
Normalized name: ordinary salt combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary dressing therapy (control group, n = 17)
Study: 22362859
Drug: Vilanterol trifenatate
Normalized name: Vilanterol Trifenatate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilanterol trifenatate (VI) 12.5-50 μg
Study: 22362859
Drug: Vilanterol trifenatate
Normalized name: Vilanterol Trifenatate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilanterol trifenatate (VI) 3, 6.25, 12.5, 25 and 50 μg
Study: 15825065
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral administration at 2-week intervals for 12 weeks)
Study: 12614246
Drug: LHRH agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH agonist monotherapy (group 1)
Study: 12614246
Drug: LHRH agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH agonist and chlormadinone acetate (group 2)
Study: 1809525
Drug: 5% vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% vitamin E gel
Study: 26983039
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with Tamsulosin plus Finasteride
Study: 26983039
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with Tamsulosin
Study: 23972722
Drug: 70 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 Gy salvage radiation therapy (RT)
Study: 23972722
Drug: Dummy run
Normalized name: Run Guard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dummy run (DR) treatment plan for 70 Gy
Study: 16644619
Drug: Ester-C (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ester-C (1000 mg)
Study: 16644619
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic Acid (AA) (1000 mg)
Study: 10662706
Drug: TPNGLN (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPNGLN (0.4 g x kg(‐1) x day(‐1))
Study: 2001826
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg omeprazole every morning
Study: 6354100
Drug: AF (ADM,
Approvals — FDA: no, EMA: no, PMDA: no
Description: AF (ADM, 40 mg/m2 q. 3W plus 5‐FUDS, 4 mg/kg daily)
Study: 6354100
Drug: MF (MMC,
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF (MMC, 10 mg/m2 q. 3W plus 5‐FUDS, 4 mg/kg daily)
Study: 30508988
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (RF lesions performed)
Study: 30508988
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (no RF lesions performed)
Study: 24697580
Drug: High IL-6-sR
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High IL-6-sR (≥ 37,401.36 pg/mL, highest tertile) at Year 16